The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siemens, D. R.
Right arrow Articles by Ratliff, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siemens, D. R.
Right arrow Articles by Ratliff, T. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2001, 166: 731-735.
Copyright © 2001 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix

D. Robert Siemens*, Bennett D. Elzey*, David M. Lubaroff*,{dagger},{ddagger},§,¶,||, Caitlin Bohlken§, Robert J. Jensen*, Axel Karl Swanson* and Timothy L. Ratliff1,*,{dagger},{ddagger},§,||

Departments of * Urology and {dagger} Microbiology, {ddagger} Prostate Cancer Research Group, § Immunology Program, Veterans Administration Medical Center, and || Cancer Center, University of Iowa, Iowa City, IA 52242


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Viruses are commonly used for the delivery of genes coding for tumor-associated Ags to elicit tumor-specific immune responses. The success of viral vectors has been limited in preclinical and clinical trials in part because of antiviral immunity. We investigated the ability of a collagen-based matrix (Gelfoam; Pharmacia and Upjohn, Kalamazoo, MI) to improve CTL activation by recombinant adenovirus. The data show that coinjection of Gelfoam with type 5 adenovirus recombinant for prostate-specific Ag (Ad5-PSA) enhanced CTL activation. Ad5-PSA priming in Gelfoam also abrogated the inhibitory effects of adenoviral immunity on CTL activation in mice naive to PSA but immune to adenovirus. Finally, Gelfoam enhanced immunization in a self-Ag model using type 5 adenovirus recombinant for membrane-bound OVA (Ad5-mOVA) in rat insulin promoter (RIP)-mOVA-transgenic mice. Thus, Gelfoam enhances CTL activation by recombinant viral vectors in a setting where preformed Ab to the virus is present and also in a tolerant self-Ag model.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
An important objective of immunotherapy is the activation of CTL responses to tumor-associated Ags. Considerable effort has focused on the identification of relevant T cell Ags, yielding an array of Ags ranging from those unique to tumors to those shared by tumor cells and parenchymal cells of similar origin (1, 2, 3, 4, 5, 6, 7). One of the primary means of activating immunity to identified Ags is through the use of recombinant technology. Genes coding for the relevant Ag are incorporated into delivery vectors, commonly viruses, which have proven to be highly effective in generating transgene expression and in CTL activation.

A number of investigators have reported effective CTL generation with recombinant viral vectors that effectively controlled tumor growth (8, 9, 10, 11). Although viruses are effective in generating CTL-mediated antitumor activity in naive mice, the use of viruses in settings where the host has been previously exposed to the virus significantly reduces transgene expression (12, 13). Studies by Yang and associates formally demonstrated that T cell responses, specifically CTL, to viral proteins were responsible for destruction of cells expressing the transgene (12). Furthermore, Abs in the serum diminish the ability of viruses to deliver the transgene (13), and the resulting decrease in gene expression reduces subsequent CTL activation (14, 15, 16, 17). The diminished ability to generate CTL, when Abs to the viral vector are present, has been suggested to be an important reason for the lack of CTL after adenovirus delivery of melanoma Ags in clinical trials (18).

Numerous attempts to circumvent the adverse effects of viral immunity on gene expression and immune activation have been reported, including boosting regimens with a different viral vector (19) and inhibiting the host anti-viral immune response with agents such as soluble TNF receptor (20), CTLA4Ig (21), or cyclophosphamide (22). The collagen-based matrix, Gelfoam (Pharmacia and Upjohn, Kalamazoo, MI) is primarily used as an intraoperative hemostatic agent, but also has been used to deliver a number of different compounds, including insulin (23), various cytokines, and growth factors (24, 25), to improve and sustain delivery. We have recently reported the use of Gelfoam as a solid-state delivery vehicle that significantly enhanced subsequent gene expression and improved tumor inhibition in an in situ immunotherapy protocol (26). Here, we demonstrate the ability of Gelfoam to enhance the generation of CTL, both in the presence of neutralizing Abs to the delivery virus as well as in a self-Ag model.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals and tumor cells

The BALB/c murine prostate cancer model, RM-11, was obtained from Dr. Timothy C. Thompson (Baylor College of Medicine, Houston, TX) (27). A RM-11psa clone was obtained by transfecting the full-length prostate-specific Ag (PSA)2 cDNA (provided by Donald Tindall, Mayo Clinic, Rochester, MN) into pH{beta}Apr-1-neo (28). RM-11neo was generated in like manner with the pH{beta}Apr-1-neo vector alone (RM-11neo). A second PSA-expressing line, the DBA/2 (H-2d) mastocytoma cell line P815, was transfected with pH{beta}Apr-1-neo-PSA (P815psa). The murine T cell lymphoma cell line, EL-4 and the OVA-expressing EL-4 cell line, EG.7, were used for CTL assays in the self-Ag model, rat insulin promoter (RIP)-mOVA-transgenic mice (29). Mice were either bred in our animal facility (RIP-mOVA) or obtained through the National Cancer Institute. All animal studies were approved by the University of Iowa Animal Review Board and were performed in accordance with institutional guidelines.

Gene transfer vectors

A replication-deficient type 5 adenovirus recombinant for PSA (Ad5-PSA) expressed from the CMV promoter was generated using standard methods by the University of Iowa Gene Transfer Vector Core (Iowa City, IA) (30). Briefly, the entire coding sequence of PSA cloned into pAd5CMVK-NpA. The resultant plasmid and adenovirus backbone sequences that had the E1 (E1A and E1B) genes deleted were transfected into human embryonic kidney (HEK) 293 cells, and viral particles were isolated and amplified for analysis of PSA expression. Type 5 adenovirus recombinant for OVA (Ad5-mOVA) used for experiments in the self-Ag model, as well as the control vector Ad5-lacZ (31), were prepared as described for Ad5-PSA.

Delivery system and immunizations

Gelfoam is a collagen matrix prepared from purified pork skin collagen (23, 24, 25, 26). Preparation of the viral vectors in the Gelfoam for injections was performed as previously described (26). The matrix/virion mixture was injected s.c. into the flanks of mice. CTL activity induced by matrix-delivered vectors was compared with s.c. injection of the same number of viral particles without matrix (fluid phase).

To investigate possible benefit of Ad5-PSA immunization with Gelfoam in the presence of anti-adenovirus Abs, mice were injected i.p. with Ad5-lacZ (109 PFU) 2 wk before immunization with Ad5-PSA. Control mice were injected i.p. with PBS. Serum samples were obtained before and after immunization and subsequently assayed for adenovirus-specific Ab titers.

Isolation and detection of lytic T cells

Fourteen days after virus injection, splenocytes were isolated and tested for CTL activity as previously described (17). Briefly, for PSA-specific CTL, splenocytes were incubated in 24-well plates at 1 x 107 cells/well together with the mitomycin C-treated P815psa stimulator cells (4 x 105) in DMEM supplemented with 10% FCS, 5 x 10-5 M 2-ME, and 10 IU/ml recombinant human (rh)IL-2. The CTL assays in the RIP-mOVA self-Ag model were performed in a similar fashion, except that in vitro stimulation was performed as a 5-day coculture with Ad5-mOVA-infected dendritic cells or SIINFEKL-pulsed 1500 cGy irradiated syngeneic spleen cells as stimulators (17, 32, 33). CD8-depleted effector cells were obtained by depleting CD8+ T cells after the 5-day culture with the Vario Macs magnetic bead system (Miltenyi Biotec, Auburn, CA) as described by the manufacturer. CD8-depleted effector cells contained <2% CD8+ T cells as determined by flow cytometry.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Effect of matrix on CTL activation

Previous studies demonstrated that Gelfoam enhanced the distribution and expression of genes delivered by viral vectors in vivo (26). To determine whether Gelfoam also enhanced CTL activation, Ad5-PSA (1 x 107–1 x 109 PFU) was injected into BALB/c mice with and without Gelfoam. Injection of mice with Ad5-lacZ (1 x 109 PFU) served as a negative control. Detection of CTL against PSA-expressing targets was observed without Gelfoam only at the highest virion concentration (1 x 109 PFU; Fig. 1GoA). Immunization with Gelfoam consistently demonstrated significant specific lysis at lower virion concentrations (1 x 107–1 x 109 PFU, Fig. 1GoB) in at least three separate experiments. Further studies in which either CD8+ T cells were depleted with anti-CD8 mAb (clone 2.43) or anti-CD8 was added to the lytic assay resulted in abrogation of lysis, demonstrating the effector cell population to be CD8+ T cells (data not shown).



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 1. Effect of Ad5-PSA immunization with and without Gelfoam on cytolytic activity of CTL. CTL lysis was measured after immunization of BALB/c mice with escalating concentrations of Ad5-PSA (107–109 PFU) or Ad5-lacZ (109 PFU) and tested against RM-11psa cells. PSA-specific cytolytic activity was determined by lack of lysis of RM-11neo targets (<5% lysis). A, Fluid phase. Ad5-PSA was injected s.c. in PBS. B, Gelfoam. Immunization (s.c.) with Ad5-PSA in the Gelfoam (107–109 PFU). Data for all groups are presented as mean of triplicate values from spleen cells pooled from three mice. The experiment shown is representative of three separate experiments.

 
Restoration of CTL activation in adenovirus-presensitized mice

Previous studies showed diminished CTL activity to transgene products if delivered by a viral vector to which the animal was immune (14, 15, 16, 17). Because the impact of viral immunity on CTL activation has been implicated as a negative factor in clinical studies and Gelfoam showed the capacity to enhance CTL activity, we tested the effect of Ad5-PSA in Gelfoam on CTL activation in the presence of anti-adenoviral immunity (18). Mice were first injected i.p. with 1 x 109 PFU Ad5-lacZ or a similar volume of PBS. Serum anti-adenoviral Ab titers of Ad5-lacZ-injected mice from both Ad5-PSA and Ad5-PSA with Gelfoam groups showed high levels of anti-adenovirus Ab at the time of Ad5-PSA injection (52.4 and 62.1 µg/ml, respectively). Subsequently, Ad5-lacZ-primed and control mice were immunized with Ad5-PSA with and without Gelfoam. As expected, prior infection with Ad5-lacZ significantly inhibited the ability of Ad5-PSA to induce a PSA-specific CTL response (Fig. 2Go). However, immunization with the same Ad5-PSA concentration (1 x 109 PFU) delivered with Gelfoam restored PSA-specific CTL lytic activity to the levels observed in adenovirus-naive mice.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 2. Effect of the presence of anti-adenovirus Ab on Ad5-PSA immunization with and without Gelfoam. Mice were injected i.p. with 109 PFU of Ad5-lacZ or PBS 2 wk before immunization with 109 PFU Ad5-PSA delivered s.c. in the fluid phase (PBS) or Gelfoam. CTL were tested against RM-11psa and RM-11neo to demonstrate PSA specificity. Cytolytic activity of each group against RM-11neo targets was <10% for all E:T ratios. Data for all groups are presented as mean of triplicate values from spleen cells pooled from three mice. The experiment shown is representative of three separate experiments.

 
CTL in a self-Ag model

Significant improvement of immunization was demonstrated using Gelfoam as a delivery vehicle in the foreign Ag model using human PSA in a murine system, which lacks a PSA homolog. However, limited success in activating CTL has been reported in nonmutated self-Ag models (9). To determine whether viral delivery with Gelfoam would improve immunization to self-Ags, we used RIP-mOVA mice, which develop tolerance to OVA-specific peptides (29, 32). RIP-mOVA mice were immunized with Ad5-mOVA (1 x 108 PFU) with and without Gelfoam. Ad5-mOVA (1 x 108 PFU) in the fluid phase also was injected into both RIP-mOVA mice and, as a control, into normal C57BL/6 mice. Immunization of normal C57BL/6 mice demonstrated OVA-specific lysis of EG.7 target cells, whereas Ad5-mOVA immunization (i.p. or s.c.) of RIP-mOVA mice showed no OVA-specific lysis (Fig. 3Go). In contrast, Ad5-mOVA immunization in Gelfoam stimulated significant OVA-specific CTL. Lysis by cells activated with Ad5-mOVA in Gelfoam was mediated by CD8+ T cells (Fig. 3Go, inset). Moreover, histological evaluation of the pancreas from Ad5-mOVA-plus-Gelfoam-primed mice showed {beta}-islet-associated inflammation but no obvious {beta}-islet destruction (data not shown).



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 3. Effect of CTL activation by Ad5-mOVA with and without Gelfoam in an OVA-transgenic self-Ag model. Ad5-mOVA (108 PFU) was used to immunize RIP-mOVA-transgenic mice. The viral vectors were delivered in fluid phase either i.p. (IP RIP-mOVA) or s.c. (SQ RIP-mOVA), as well as in the Gelfoam (SQ RIP-mOVA). Control OVA-specific CTL activity induced by Ad5-mOVA immunization was demonstrated in a foreign Ag model by i.p. injection (fluid phase) in nontransgenic C57BL/6 mice (IP C57BL/6). Lytic activity against parental EL4 was <5% for all E:T ratios for all groups. Inset, Mice were immunized i.p. with Ad5-mOVA (108 PFU). Lytic activity was measured after the 5-day coculture with SIINFEKL-pulsed syngeneic spleen cells for unfractionated cells against EG7 (EG7 Unfractionated) or EL4 (EL4 Unfractionated) target cells or for CD8-depleted effector cells (EG7 CD8 depleted). CD8+ T cell contamination in the effector cells was <2% as determined by flow cytometry. Data for all groups are presented as mean of triplicate values from spleen cells pooled from three mice. The experiment shown is representative of two separate experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Since the first convincing demonstration of the existence of specific tumor-associated Ags (34), much interest has been stimulated in the possibilities of cancer immunotherapy. Recently, numerous reports have identified genes encoding Ags specific to tumor cells, suggesting that recombinant tumor Ags could be delivered to the host to elicit an anti-tumor immune response. Commonly, these engineered peptides or proteins have been delivered to the host as a recombinant viral vaccine using vaccinia or adenovirus. Despite the benefits of transferring genetic material in a viral vector, the presence of preexisting immunity or the development of a neutralizing immune response to viral proteins after treatment limits the use of these vectors as initial immunizing agents or for readministration to boost the response (12, 13, 14, 15, 16, 17, 18).

Several strategies have been adopted to overcome or bypass this neutralizing immune response to optimize the use of these viral vectors. Tumor Ags can be delivered as defined peptides (35), proteins designed to access the MHC class I pathway of APCs in vivo (36), or by adoptive transfer of Ag-loaded APCs such as dendritic cells (37). DNA vaccines encoding tumor Ags can be delivered as naked DNA or encapsulated by liposomes (38). Xiang et al. have recently described an autologous oral DNA vaccine delivered with an attenuated strain of Salmonella typhimurium to successfully immunize mice in a self-Ag model of melanoma (39). In addition, less immunogenic vectors have been used including adeno-associated virus, lentivirus, and gutless adenovirus. Also, avoidance of the antiviral immune response of the more immunogenic viral vectors may be possible by varying the vectors that are used for boosting the immune response (19). Finally, treatment with suppressive agents such as soluble TNF receptor (20), CTLA4Ig (21), cyclophosphamide (22), and anti-CD40 (40) has been shown to inhibit the host anti-viral immune response, improve transgene expression, and enhance the ability to use vectors for multiple injections. Although the latter suppressive approaches are effective in blocking the development of immunity to viral proteins, their use in the context of vector-induced CTL activation is controversial. Clearly, alternative approaches for gene delivery and CTL activation are needed.

Our previous data demonstrated that intratumoral injection of viral vectors in Gelfoam enhanced both the distribution and the expression level of reporter transgenes transferred by viruses (26). Furthermore, the enhanced gene delivery with the Gelfoam enhanced biologic activity of an in situ immunotherapy protocol (26). As a result of the enhanced gene delivery and augmented antitumor effects induced by coinjection of Gelfoam and recombinant viruses, we tested the effects of Gelfoam on Ad5-PSA-mediated CTL activation. Ad5-PSA was previously observed to induce CTL activity in a murine tumor model system, and to activate CTL-mediated PSA-specific antitumor activity.3 Here we show that Gelfoam enhances CD8+ CTL activation in both foreign and autologous Ag settings. Consistent with previous reports in the RIP-mOVA model where OT-1 adoptive transfer frequency was low, inflammation was observed in the pancreas but {beta}-islet destruction was not apparent (Ref. 40 , and data not shown). Importantly, we show that administration of Ad5-PSA with Gelfoam abrogated the inhibitory effects on CTL activation of preexisting immunity to adenovirus. These data suggest that coinjection of recombinant viruses with Gelfoam may provide an approach for augmenting CTL activation in the clinical setting and also may provide a means of using viral vectors for multiple injections to boost immunity.

The mechanism(s) by which Gelfoam enhances CTL priming is not known. Previous studies demonstrated that CTL priming either with pox or polio virus required MHC class I-matched bone marrow-derived cells. Interestingly, either recombinant Ag produced in the periphery or Ag produced by bone marrow-derived cells was sufficient to activate CTL (41). In this regard, distribution studies, which were performed using PCR amplification of adenoviral DNA, showed an absence of detectable DNA in the liver, lungs, and other tested organs, but adenoviral DNA was detected in the draining lymph nodes for both fluid phase and Gelfoam-delivered virus. These initial biodistribution studies were not quantitative but clearly show the presence of virus in draining lymph nodes. Perhaps Gelfoam enhances delivery to the draining nodes where higher Ag expression could enhance T cell priming (42). It is clear that the delivery of genes in Gelfoam results in a 5- to 10-fold enhancement of gene expression and an extension of the time course of expression (26). Likewise, it is known that Ag levels play an important role in CTL priming (33, 43). In this regard, Xiang and associates recently showed that by directing proteins to the proteosome, which enhanced MHC class I Ag presentation and limited Ab development, CTL activation was enhanced sufficiently to mediate antitumor activity (39). Thus, the simplest explanation for the observed ability of Gelfoam to augment CTL activation is elevated production of the transgene product, which delivers a higher Ag load to bone marrow-derived APCs. Determination of the functional role of Gelfoam is currently under investigation.


   Footnotes
 
1 Address correspondence and reprint requests to Dr. Timothy L. Ratliff, Department of Urology, University of Iowa, 200 Hawkins Drive, 3 RCP, Iowa City, IA 52242-1089. Back

2 Abbreviations used in this paper: PSA, prostate-specific Ag; Ad5-PSA, type 5 adenovirus recombinant for PSA; Ad5-mOVA, type 5 adenovirus recombinant for OVA; RIP, rat insulin promoter. Back

3 B. D. Elzey, D. R. Siemens, T. L. Ratliff, and D. M. Lubaroff. Immunization with type 5 adenovirus recombinant for PSA in combination with ALVAC cytokine gene delivery induces destruction of established prostate tumors. Submitted for publication. Back

Received for publication June 14, 2000. Accepted for publication November 21, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Boon, T., J. Cerottini, B. Van den Eynde, P. Van der Bruggen, A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.[Medline]
  2. Hellstrom, I., H. J. Garrigues, U. Garrigues, K. E. Hellstrom. 1990. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cells surface antigens. Cancer Res. 50:2183.[Abstract/Free Full Text]
  3. Kim, J., T. K. Park, S. Hu, K. E. Hellstrom. 1995. Defining the molecular recognition of GLOBO H (human breast cancer) antigen through probe structures prepared by total synthesis. J. Org. Chem. 60:7716.
  4. Israeli, R. S., T. Powell, J. G. Corr, W. R. Fair, W. D. Heston. 1994. Expression of prostate-specific membrane antigen. Cancer Res. 54:1807.[Abstract/Free Full Text]
  5. Carrato, C., C. Balague, C. De Bolos, E. Gonzalez, G. Gambus, J. Planas, J. M. Perini, D. Andrea, F. X. Real. 1994. Differential apomucin expression in normal and neoplastic tissues. Gastroenterology 107:160.[Medline]
  6. Pardoll, D. M.. 1994. Tumor antigens: a new look for the 1990s. Nature 369:357.[Medline]
  7. Rosenberg, S. A.. 1996. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88:1635.[Abstract/Free Full Text]
  8. McCabe, B. J., K. R. Irvine, M. I. Nishimura, J. C. Yang, P. J. Spiess, E. P. Shulman, S. A. Rosenberg, N. P. Restifo. 1994. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T cell responses. Cancer Res. 55:1741.[Abstract/Free Full Text]
  9. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, J. W. Greiner. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59:676.[Abstract/Free Full Text]
  10. Tsang, K., Y. Zaremba, S. Nieroda, C. A. Zhu, M. Z. Hamilton, J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:982.[Abstract/Free Full Text]
  11. Zhai, Y., J. C. Yang, Y. Kawakami, P. Spiess, S. C. Wadsworth, L. M. Cardoza, L. A. Couture, A. E. Smith, S. A. Rosenberg. 1996. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer. J. Immunol. 156:700.[Abstract]
  12. Yang, Y., H. C. Ertl, J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433.[Medline]
  13. Kuriyama, S., K. Tominaga, M. Kikukawa, T. Nakatani, H. Tsujinoue, M. Yamazaki, S. Nagao, Y. Toyokawa, A. Mitoro, H. Fukui. 1998. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res. 18:2345.[Medline]
  14. Mullbacher, A., A. Bellett, R. Hla. 1989. The murine cellular immune response to adenovirus type 5. Immunol. Cell Biol. 67:31.
  15. Julliard, V., P. Villefroy, D. Godfrin, A. Pavirani, A. Venet, J. G. Guillet. 1995. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25:3467.[Medline]
  16. Yang, Y., Q. Li, H. C. J. Ertl, J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004.[Abstract]
  17. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, M. J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270.[Abstract]
  18. Rosenberg, S. A., Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, et al 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1894.[Abstract/Free Full Text]
  19. Irvine, K. R., R. S. Chamberlain, E. P. Shulman, D. R. Surman, S. A. Rosenberg, N. P. Restifo. 1997. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89:1595.[Abstract/Free Full Text]
  20. Zhang, H. G., T. Zhou, P. Yang, C. K. Edwards 3rd, D. T. Curiel, J. D. Mountz. 1998. Inhibition of tumor necrosis factor {alpha} decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum. Gene Ther. 9:1875.[Medline]
  21. Jooss, K., L. A. Turka, J. M. Wilson. 1998. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5:309.[Medline]
  22. Jooss, K., Y. Yang, J. M. Wilson. 1996. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther. 7:1555.[Medline]
  23. Lee, Y. C., P. Simamora, S. H. Yalkowsky. 1997. Systemic delivery of insulin via an enhancer-free ocular device. J. Pharm. Sci. 86:1361.[Medline]
  24. Segal, D. H., I. M. Germano, J. B. Berderson. 1997. Effects of basic fibroblast growth factor on in vivo cerebral tumorigenesis in rats. Neurosurgery 40:1027.[Medline]
  25. Watanabe, M., K. L. McCormick, K. Volker, J. R. Ortaldo, J. M. Wigginton, M. J. Brunda, R. H. Wiltrout, W. E. Fogler. 1997. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. J. Pathol. 150:1869.[Abstract]
  26. Siemens, D. R., J. C. Austin, S. P. Hedican, J. Tartaglia, T. L. Ratliff. 2000. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model. J. Natl. Cancer Inst. 92:403.[Abstract/Free Full Text]
  27. Baley, P. A., K. Yoshida, W. Qian, I. Sehgal, T. C. Thompson. 1996. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J. Steroid Biochem. Mol. Biol. 52:403.
  28. Gunning, P., J. Leavitt, G. Muscat, S. Y. Ng, L. Kedes. 1987. A human {beta}-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA 84:4831.[Abstract/Free Full Text]
  29. Kurts, C., W. R. Heath, H. Kosaka, J. F. Miller, F. R. Carbone. 1998. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J. Exp. Med. 188:415.[Abstract/Free Full Text]
  30. Ooboshi, H., Y. Chu, C. D. Rios, F. M. Faraci, B. L. Davidson, D. D. Heistad. 1997. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase. Am. J. Physiol. Heart Circ. Physiol. 273:H265.[Abstract/Free Full Text]
  31. Jaffe, H. A., C. Danel, G. Longenecker, M. Metzger, Y. Setoguchi, M. A. Rosenfeld, T. W. Gant, S. S. Thorgeirsson, L. D. Stratford-Perricaudet, M. Perricaudet, et al 1992. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1:372.[Medline]
  32. Sigal, L. J., S. Crotty, R. Andino, K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398:77.[Medline]
  33. Kurts, C., R. M. Sutherland, G. Davey, M. Li, A. M. Lew, E. Blanas, F. R. Carbone, J. F. Miller, W. R. Heath. 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96:12703.[Abstract/Free Full Text]
  34. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.[Abstract/Free Full Text]
  35. Prehn, R. T., J. M. Main. 1957. Immunity to methylcholanthrene induced sarcomas. J. Natl. Cancer Inst. 18:769.
  36. Henderson, R. A., O. J. Finn. 1996. Human tumor antigens are ready to fly. Adv. Immunol. 62:217.[Medline]
  37. Falo, L. D., M. Kovacovics-Bankowski, K. Thompson, K. L. Rock. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity. Nat. Med. 1:649.[Medline]
  38. Celluzi, C. M., J. I. Mayordoomo, W. J. Storkus, M. T. Lotze, L. D. Falo. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.[Abstract/Free Full Text]
  39. Norman, A., S. Parker, D. Lew, M. Manthrope, M. Marquet. 1995. Preclinical pharmacokinetics, manufacturing and safety studies supporting a multicenter cancer gene therapy trial. Hum. Gene Ther. 6:549.[Medline]
  40. Xiang, R., H. N. Lode, T. H. Chao, J. M. Ruehlmann, C. S. Dolman, F. Rodriguez, J. L. Whitton, W. W. Overwijk, N. P. Restifo, R. A. Reisfeld. 2000. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. USA 97:5492.[Abstract/Free Full Text]
  41. Ito, D., K. Ogasawara, K. Iwabuchi, Y. Inuyama, K. Onoe. 2000. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J. Immunol. 164:1230.[Abstract/Free Full Text]
  42. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. A. P. Miller, H. Kosaka. 1996. Constitutive class-I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923.[Abstract/Free Full Text]
  43. Bullock, T. N., T. A. Colella, V. H. Engelhard. 2000. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164:2354.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
B. D. Elzey, N. W. Schmidt, S. A. Crist, T. P. Kresowik, J. T. Harty, B. Nieswandt, and T. L. Ratliff
Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge
Blood, April 1, 2008; 111(7): 3684 - 3691.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. VanOosten and T. S. Griffith
Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy
Cancer Res., December 15, 2007; 67(24): 11980 - 11990.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Liu, D. P. Evanoff, X. Chen, and Y. Luo
Urinary Bladder Epithelium Antigen Induces CD8+ T Cell Tolerance, Activation, and Autoimmune Response
J. Immunol., January 1, 2007; 178(1): 539 - 546.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siemens, D. R.
Right arrow Articles by Ratliff, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siemens, D. R.
Right arrow Articles by Ratliff, T. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS